Recently, Guangzhou Deep Medical Device Technology Co., Ltd. (“Deep Medical”), an enterprise specializing in microscopic surgical robots, announced the completion of its Series A financing, led by Kangjun Capital, a professional medical fund with strong industrial background. The proceeds will further accelerate its clinical trials, regulatory registration, and domestic and international market expansion.
Integration of Medicine and Engineering: A Two-Way Collaboration
Founded in 2013, Deep Medical is an innovative medical device company focused on the R&D and clinical application of microsurgical robots. As a founding member of the Chinese Microsurgery Association, the company is committed to developing intelligent devices covering full-scenario operations under microscopes, addressing pain points such as high operational intensity and strict precision requirements in microsurgery, and filling gaps in China’s microsurgical robot sector.
Its core technology originates from a clinical translation project at the First Affiliated Hospital of Sun Yat-sen University, integrating practical expertise from leading domestic microsurgery specialists. The project was selected as one of Guangdong Province’s Excellent Medical Achievements 2024 and among the Top 8 Advances in Microsurgery.
Dr. Xia Jun, the founder, is an expert in the cross-field of medicine and engineering, with long-term dedication to surgical robot R&D and clinical application. He led his team to successfully develop and commercialize China’s first and the world’s second ophthalmic microsurgical robot. His proposed “Multi-point Remote Master Control (MRMC)” architecture effectively resolves critical challenges including physiological tremor and surgeon fatigue, driving technological breakthroughs in the field.
Over 80% of the company’s employees are core R&D personnel, with more than 50% holding master’s degrees or above. The core founding team led the R&D and commercialization of the aforementioned ophthalmic microsurgical robot during their doctoral studies.
World’s First “What You See Is Where You Reach” Microsurgical System
Deep Medical’s independently developed FUNZAR Microsurgical Robot System — the world’s first modular universal microscopic surgical robot — has been recognized as a major advancement in the field by the Microsurgery Branch of the Chinese Medical Association for two consecutive years (2024 and 2025), and ranked first among the Top 5 Annual Advances in 2025. It is now in Phase III NMPA clinical trials for registration.
The system innovatively upgrades from a “microscope” to a complete “microsystem,” and is expected to redefine the standard of microscopic surgery.
FUNZAR features dual robotic arms with 16 degrees of freedom, a 60× 4K ultra-high-definition 3D digital vision navigation system, modular technology, and master-slave control with submicron spatial positioning. Its core functions cover full-scenario microsurgery, including open and minimally invasive intraluminal procedures, applicable to hands, feet, head and neck, and in volving lymphatic, venous and arterial tissues, with broad surgical adaptability.
Three Core Innovative Advantages:
Hand-Eye Integrated Operation: The world’s first high-magnification system (10–100×) integrating pure digital vision and dexterous robotic arms, enabling “what you see is where you reach” precision.
Multi-Arm Collaboration: World-leading small modular design supporting flexible configuration of multiple arms, enabling unmanned microsurgery and reducing reliance on surgical assistants.
Universal Architecture: Based on PCT-patented MRMC technology, it is the only system in the industry covering both ophthalmic and non-ophthalmic microsurgery (microsurgical reconstruction, neurosurgery, orthopedics, ENT, etc.).
The system also provides adaptive force closed-loop feedback and a split modular design, ensuring surgical safety while adapting to limited operating room space.
As a universal platform compatible with multiple procedures, FUNZAR adopts a “universal platform + specialized consumables” business model, delivering strong scalability and market penetration.
Since its official launch in April 2024, Deep Medical has efficiently completed product development, animal testing, type inspection, scientific human trials, and enrollment for registration clinical studies. Since entering clinical validation in December 2024, FUNZAR trials have been conducted at top hospitals in Beijing, Shanghai, Changsha, Guangzhou and other cities. Dozens of completed patient cases have fully validated its technological superiority and stability.
Outlook
According to QYResearch, the global microsurgical robot market is at a critical stage of transitioning from technical verification to large-scale commercial application. The global market size reached $571 million in 2024 and is projected to grow to $1.989 billion by 2031, with a CAGR of 19.5%.
China is the fastest-growing market, with a five-year CAGR of 34.5%, and its market size is expected to exceed 11 billion RMB in 2025.
While North America remains dominant, China is becoming the world’s most promising incremental market. Amid this industrial window of technological breakthrough and commercialization, Deep Medical — backed by its globally pioneering technology, rapidly advancing clinical validation, and clear commercial path — is poised to fill gaps in the domestic market.
